Verve Therapeutics, Inc. (VERV) News

Verve Therapeutics, Inc. (VERV): $13.35

-0.26 (-1.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VERV to Watchlist
Sign Up

Industry: Biotech


Ranked

of 392

in industry

Filter VERV News Items

VERV News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VERV News Highlights

  • VERV's 30 day story count now stands at 2.
  • Over the past 14 days, the trend for VERV's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BASE and GENE are the most mentioned tickers in articles about VERV.

Latest VERV News From Around the Web

Below are the latest news stories about Verve Therapeutics Inc that investors may wish to consider to help them evaluate VERV as an investment opportunity.

Verve Therapeutics (VERV) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

Verve Therapeutics Announces 2022 Anticipated Milestones and Preclinical Data on Potential Additional Dosing Regimens for its Novel Base Editing Programs

VERVE-101 Regulatory Submissions and First Patient Treated On-track for Second Half of 2022 ANGPTL3 Program Initiation of IND-Enabling Studies Expected in the Second Half of 2022 Preclinical Data in Non-Human Primates Demonstrate Potential to Re-Dose or Sequentially Dose Base Editing Programs CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., (Nasdaq: VERV), a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene

Yahoo | January 10, 2022

Verve Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 4:30 p.m. ET. A live webcast will be available in the investor section of the company's website at www.vervetx.com. The w

Yahoo | January 3, 2022

Verve Therapeutics Inc Insiders are Selling. Investors Should Take Notice

GuruFocus data shows that Sekar Kathiresan, CEO of Verve Therapeutics Inc ( NA:VERV), sold 48.693 shares on December 28, 2021.

Yahoo | December 29, 2021

3 Synthetic Biology Stocks in Focus With Strong Potential

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Yahoo | December 24, 2021

Penn Series Small Cap Index Fund Buys AMC Entertainment Holdings Inc, DigitalOcean Holdings ...

Investment company Penn Series Small Cap Index Fund (Current Portfolio) buys AMC Entertainment Holdings Inc, DigitalOcean Holdings Inc, Coursera Inc, Sana Biotechnology Inc, Butterfly Network Inc, sells , Macquarie Infrastructure Holdings LLC, MultiPlan Corp, , Sykes Enterprises Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Penn Series Small Cap Index Fund.

Yahoo | December 11, 2021

Insider Buying: Verve Therapeutics, Inc. (NASDAQ:VERV) Director Acquires 4,700 Shares of Stock

Verve Therapeutics, Inc. (NASDAQ:VERV) Director Burt A. Adelman bought 4,700 shares of Verve Therapeutics stock in a transaction dated Thursday, December 2nd. The shares were bought at an average cost of $31.34 per share, with a total value of $147,298.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can []

Transcript Daily | December 9, 2021

Royal Bank of Canada Makes New Investment in Verve Therapeutics, Inc. (NASDAQ:VERV)

Royal Bank of Canada bought a new position in shares of Verve Therapeutics, Inc. (NASDAQ:VERV) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm bought 7,100 shares of the companys stock, valued at approximately $428,000. A number of other hedge funds also recently made changes to their positions []

Transcript Daily | December 8, 2021

Insider Buying: The Verve Therapeutics, Inc. (NASDAQ:VERV) Co-Founder & Independent Chairman of the Board Just Bought 1.1% More Shares

Potential Verve Therapeutics, Inc. ( NASDAQ:VERV ) shareholders may wish to note that the Co-Founder & Independent...

Yahoo | December 8, 2021

Verve Therapeutics (NASDAQ:VERV) Stock Price Up 11.6% Following Insider Buying Activity

Verve Therapeutics, Inc. (NASDAQ:VERV)s share price rose 11.6% during trading on Tuesday after an insider bought additional shares in the company. The company traded as high as $36.04 and last traded at $35.90. Approximately 7,700 shares traded hands during trading, a decline of 98% from the average daily volume of 401,452 shares. The stock had []

Dakota Financial News | December 7, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5797 seconds.